People

Gerhard Koenig

augustinetx.com

Dr. Koenig took up his role as CEO of Augustine Therapeutics in January 2025 having served as a Non-Executive Director since May 2022, and as Executive Chairman since June 2024. Gerhard was CEO and Co-founder of Arkuda Therapeutics, a Boston-based biotech company focused on the development of lysosomal function enhancers for the treatment of neurodegenerative diseases including Alzheimer’s Disease and Parkinson’s Disease. Arkuda’s portfolio of lysosomal function enhancers was acquired by Johnson & Johnson, which was announced in January 2025. He is an advisor with Atlas Venture, a Boston-based VC fund, and is Board member on VIGIL Therapeutics. Prior to his current positions, Gerhard served as CEO of Quartet Medicine, CSO and Senior Vice President of FORUM Pharmaceuticals, Vice President of Scientific Programs and Evaluation at Fidelity Biosciences Group (now F' Prime Capital), and held multiple positions at pharmaceutical company Bayer. Gerhard received his PhD and MS degrees in molecular and cellular neurobiology with a minor in biochemistry, graduating summa laude from the University of Heidelberg, Germany. Historical affiliation correction: Augustine’s published biography still names a Vigil board appointment. Vigil Neuroscience’s SEC closing report explicitly records Gerhard Koenig’s board resignation effective August 5, 2025, following Sanofi’s acquisition. His Vigil board appointment is therefore historical, and no current Vigil directorship is asserted.